TheStreet's Jim Cramer is asked for advice on Mannkind, which has doubled in value after an FDA panel recommended approval of its insulin drug Afreeza, but has dropped off after the FDA delayed its decision. Cramer says Visa is getting "clubbed" and he needs to look into the credit card companies a little more, but FireEye is a "high-flyer." Finally, Cramer says he is unsure if Linn Energy's recently-declared dividend is safe. Send your Twitter questions to #CramerQ on Monday mornings.

More from Video

60 Seconds: What is the Yield Curve and Why is Everyone Talking About It?

60 Seconds: What is the Yield Curve and Why is Everyone Talking About It?

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

Millennials Love Investing in Timeshares: Bluegreen Vacations CEO

Millennials Love Investing in Timeshares: Bluegreen Vacations CEO

60 Seconds: What's the Difference Between an ETF and a Mutual Fund?

60 Seconds: What's the Difference Between an ETF and a Mutual Fund?

Amazon's One-Year Anniversary of Buying Whole Foods: A Whole Lot of Silly Hype

Amazon's One-Year Anniversary of Buying Whole Foods: A Whole Lot of Silly Hype